First Trust Advisors LP lowered its stake in shares of Halyard Health, Inc. (NYSE:HYH) by 28.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,004 shares of the medical instruments supplier’s stock after selling 7,830 shares during the period. First Trust Advisors LP’s holdings in Halyard Health were worth $786,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Capstone Asset Management Co. bought a new position in Halyard Health in the 1st quarter worth approximately $203,000. Oregon Public Employees Retirement Fund boosted its holdings in Halyard Health by 1.2% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 16,303 shares of the medical instruments supplier’s stock worth $621,000 after buying an additional 200 shares during the period. State Treasurer State of Michigan boosted its holdings in Halyard Health by 0.5% in the 1st quarter. State Treasurer State of Michigan now owns 18,920 shares of the medical instruments supplier’s stock worth $721,000 after buying an additional 100 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in Halyard Health by 11.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 32,077 shares of the medical instruments supplier’s stock worth $1,222,000 after buying an additional 3,230 shares during the period. Finally, American Century Companies Inc. bought a new position in Halyard Health in the 1st quarter worth approximately $1,646,000. Institutional investors own 91.02% of the company’s stock.

Halyard Health, Inc. (NYSE HYH) opened at 46.07 on Friday. Halyard Health, Inc. has a 12-month low of $31.59 and a 12-month high of $46.36. The company has a 50-day moving average of $43.72 and a 200 day moving average of $39.69. The company has a market capitalization of $2.15 billion, a P/E ratio of 44.30 and a beta of 1.76.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.14. The company had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. Halyard Health’s revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the business earned $0.45 EPS. Equities research analysts forecast that Halyard Health, Inc. will post $1.97 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/23/halyard-health-inc-hyh-shares-sold-by-first-trust-advisors-lp.html.

Several research analysts recently commented on HYH shares. TheStreet raised shares of Halyard Health from a “c” rating to a “b” rating in a report on Thursday, June 22nd. BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Wednesday, July 12th. Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a report on Thursday, August 3rd. Finally, Deutsche Bank AG raised their price objective on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.25.

Halyard Health Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health, Inc. (NYSE:HYH).

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.